Clinical and biological effects of gefitinib in EGFR fish positive/phospho-AKT positive or never smoker non-small cell lung cancer (NSCLC): Results of the ONCOBELL trial

被引：0
|
作者：
Cappuzzo, F.
Toschi, L.
Trisolini, R.
Bartolini, S.
Magrini, E.
Domenichini, I
Metro, G.
Crino, L.
Ciardiello, F.
Varella-Garcia, M.
机构：
[1] Univ Bologna, Osped Bellaria, Bologna, Italy
[2] Univ Perugia, Monteluce Policlin, Perugia, Italy
[3] CINECA, Bologna, Italy
[4] Seconda Univ Napoli, Naples, Italy
[5] Univ Colorado, Ctr Canc, Aurora, CO USA
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：XI25 / XI25
页数：1
相关论文
共 50 条
  • [21] Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer
    Lilenbaum, Rogerio A.
    Horn, Leora A.
    [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2016, 14 (5.5): : 672 - 674
  • [22] Phospho-akt overexpression in non-small cell lung cancer confers significant stage-independent survival disadvantage
    David, O
    LeBeau, H
    Brody, AR
    Friedman, M
    Jett, J
    [J]. CHEST, 2004, 125 (05) : 152S - 152S
  • [23] Differential effects of gefitinib and cetuximab on EGFR mutant non-small cell lung cancers (NSCLC) cell lines
    Mukohara, T
    Engelman, J
    Lindeman, N
    Pearlberg, J
    Cantley, L
    Johnson, B
    Jänne, P
    [J]. LUNG CANCER, 2005, 49 : S7 - S7
  • [24] Effects of STAT3 polymorphisms and pharmacokinetics on the clinical outcomes of gefitinib treatment in patients with EGFR-mutation positive non-small cell lung cancer
    Yokota, Hayato
    Sato, Kazuhiro
    Sakamoto, Sho
    Okuda, Yuji
    Asano, Mariko
    Takeda, Masahide
    Nakayama, Katsutoshi
    Miura, Masatomo
    [J]. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2020, 45 (04) : 652 - 659
  • [25] Clinical Activity of Osimertinib in EGFR Mutation Positive Non-Small Cell Lung Cancer (NSCLC) Patients (Pts) Previously Treated with Rociletinib
    Gadgeel, Shirish
    Chen, Wei
    Piotrowska, Zofia
    Goldman, Jonathan W.
    Wakelee, Heather
    Camidge, D. Ross
    Varga, Andrea
    Yu, Helena
    Papadimitrakopoulou, Vassiliki
    Nea, Joel
    Soria, Jean-Charles
    Wozniak, Antoinette
    Riely, Gregory
    Narayanan, Vignesh
    Mendenhal, Melody
    Sequist, Lecia
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1263 - S1263
  • [26] Phospho-Akt overexpression in non-small cell lung cancer confers significant stage-independent survival disadvantage
    David, O
    Jett, J
    LeBeau, H
    Dy, G
    Hughes, J
    Friedman, M
    Brody, AR
    [J]. CLINICAL CANCER RESEARCH, 2004, 10 (20) : 6865 - 6871
  • [27] CLINICAL CHARACTERISTICS OF NON-SMALL CELL LUNG CANCER WITH EGFR MUTATIONS IN NEVER SMOKERS
    Park, Young Sik
    Park, Ju-Hee
    Lee, Jinwoo
    Lee, Sang-Min
    Lee, Chang-Hoon
    Yim, Jae-Joon
    Yoo, Chul-Gyu
    Han, Sung Koo
    Kim, Young Tae
    Heo, Dae Seog
    Kim, Young Whan
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1283 - S1283
  • [28] Clinical development of RET inhibitors for RET fusion positive non-small cell lung cancer (NSCLC)
    Goto, Koichi
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S271 - S271
  • [29] Association of the EGFR gene polymorphisms with clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC) treated with gefitinib
    Ma, F.
    Lin, D.
    Sun, T.
    Chu, D.
    Zhang, X.
    Wang, Z.
    Wang, J.
    Shi, Y.
    Sun, Y.
    Xu, B.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [30] Catechol estrogen profiles of patients with EGFR- and ALK-positive non-small cell lung cancer (NSCLC)
    Bodor, J. Nicholas
    Treat, Joseph
    Krzizike, Daniel D.
    Zawislak, Carolyn L.
    Vanderveer, Lisa
    Eidbo, Sarah
    Ross, Eric A.
    Edelman, Martin J.
    Andrews, Andrew J.
    Clapper, Margie L.
    [J]. CANCER RESEARCH, 2022, 82 (12)
12345